Twice-yearly exams unnecessary for patients taking quetiapine

Frederick W. Fraunfelder

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

To determine the necessity for the heightened level of monitoring for cataract development in patients taking quetiapine (Seroquel, AstraZeneca Pharmaceuticals, Wilmington, Delaware) dictated by the Physicians' Desk Reference. Also, to explore the possibility of cataractogenesis because of quetiapine therapy. Observational case series. Data were garnered from a series of 80 case reports collected at the National Registry of Drug-Induced Ocular Side Effects (Portland, Oregon). The World Health Organization (WHO) causality assessment guidelines were used to assess the relationship between quetiapine and cataractogenesis. There were 34 reports of cataracts associated with quetiapine therapy. Average age was 44 years with 23 females and 11 males studied. Average duration of therapy was 29.3 weeks on standard doses. Cataractogenesis secondary to quetiapine is unlikely by WHO guidelines. This probably makes it unnecessary to require biannual ophthalmic examinations as routine eye examinations are sufficient to screen for this condition.

Original languageEnglish (US)
Pages (from-to)870-871
Number of pages2
JournalAmerican Journal of Ophthalmology
Volume138
Issue number5
DOIs
StatePublished - Nov 2004

Fingerprint

Cataract
Guidelines
Causality
Pharmaceutical Preparations
Registries
Quetiapine Fumarate
Therapeutics
Physicians

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Twice-yearly exams unnecessary for patients taking quetiapine. / Fraunfelder, Frederick W.

In: American Journal of Ophthalmology, Vol. 138, No. 5, 11.2004, p. 870-871.

Research output: Contribution to journalArticle

Fraunfelder, Frederick W. / Twice-yearly exams unnecessary for patients taking quetiapine. In: American Journal of Ophthalmology. 2004 ; Vol. 138, No. 5. pp. 870-871.
@article{1b5e74003dd64642a0e13bd9f1e0c1c4,
title = "Twice-yearly exams unnecessary for patients taking quetiapine",
abstract = "To determine the necessity for the heightened level of monitoring for cataract development in patients taking quetiapine (Seroquel, AstraZeneca Pharmaceuticals, Wilmington, Delaware) dictated by the Physicians' Desk Reference. Also, to explore the possibility of cataractogenesis because of quetiapine therapy. Observational case series. Data were garnered from a series of 80 case reports collected at the National Registry of Drug-Induced Ocular Side Effects (Portland, Oregon). The World Health Organization (WHO) causality assessment guidelines were used to assess the relationship between quetiapine and cataractogenesis. There were 34 reports of cataracts associated with quetiapine therapy. Average age was 44 years with 23 females and 11 males studied. Average duration of therapy was 29.3 weeks on standard doses. Cataractogenesis secondary to quetiapine is unlikely by WHO guidelines. This probably makes it unnecessary to require biannual ophthalmic examinations as routine eye examinations are sufficient to screen for this condition.",
author = "Fraunfelder, {Frederick W.}",
year = "2004",
month = "11",
doi = "10.1016/j.ajo.2004.05.038",
language = "English (US)",
volume = "138",
pages = "870--871",
journal = "American Journal of Ophthalmology",
issn = "0002-9394",
publisher = "Elsevier USA",
number = "5",

}

TY - JOUR

T1 - Twice-yearly exams unnecessary for patients taking quetiapine

AU - Fraunfelder, Frederick W.

PY - 2004/11

Y1 - 2004/11

N2 - To determine the necessity for the heightened level of monitoring for cataract development in patients taking quetiapine (Seroquel, AstraZeneca Pharmaceuticals, Wilmington, Delaware) dictated by the Physicians' Desk Reference. Also, to explore the possibility of cataractogenesis because of quetiapine therapy. Observational case series. Data were garnered from a series of 80 case reports collected at the National Registry of Drug-Induced Ocular Side Effects (Portland, Oregon). The World Health Organization (WHO) causality assessment guidelines were used to assess the relationship between quetiapine and cataractogenesis. There were 34 reports of cataracts associated with quetiapine therapy. Average age was 44 years with 23 females and 11 males studied. Average duration of therapy was 29.3 weeks on standard doses. Cataractogenesis secondary to quetiapine is unlikely by WHO guidelines. This probably makes it unnecessary to require biannual ophthalmic examinations as routine eye examinations are sufficient to screen for this condition.

AB - To determine the necessity for the heightened level of monitoring for cataract development in patients taking quetiapine (Seroquel, AstraZeneca Pharmaceuticals, Wilmington, Delaware) dictated by the Physicians' Desk Reference. Also, to explore the possibility of cataractogenesis because of quetiapine therapy. Observational case series. Data were garnered from a series of 80 case reports collected at the National Registry of Drug-Induced Ocular Side Effects (Portland, Oregon). The World Health Organization (WHO) causality assessment guidelines were used to assess the relationship between quetiapine and cataractogenesis. There were 34 reports of cataracts associated with quetiapine therapy. Average age was 44 years with 23 females and 11 males studied. Average duration of therapy was 29.3 weeks on standard doses. Cataractogenesis secondary to quetiapine is unlikely by WHO guidelines. This probably makes it unnecessary to require biannual ophthalmic examinations as routine eye examinations are sufficient to screen for this condition.

UR - http://www.scopus.com/inward/record.url?scp=7544243799&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=7544243799&partnerID=8YFLogxK

U2 - 10.1016/j.ajo.2004.05.038

DO - 10.1016/j.ajo.2004.05.038

M3 - Article

C2 - 15531330

AN - SCOPUS:7544243799

VL - 138

SP - 870

EP - 871

JO - American Journal of Ophthalmology

JF - American Journal of Ophthalmology

SN - 0002-9394

IS - 5

ER -